Key facts
- Notable investors include BoxOne Ventures, Magnify.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for EndoFold
- ·The full record, as it builds
Funding rounds
No funding rounds for EndoFold are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EndoFold
Developer of a gene delivery platform designed to deliver genetic material for the treatment of cancer, immune, and musculoskeletal diseases. The company offers human protein-based RNA carriers, a computational testing platform, and targeted delivery methods, enabling biotech researchers to develop non-viral therapies with reduced immune activation.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 9
- Website
- endofold.bio/
- Ownership
- Privately Held (backing)
EndoFold doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EndoFold shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EndoFold in its N-PORT filings yet. We sweep new filings monthly.